NDAINTRAVESICALSYSTEMPriority Review
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
INLEXZO (gemcitabine intravesical) by Johnson & Johnson is nucleic acid synthesis inhibitors [moa]. Approved for nucleoside metabolic inhibitor [epc]. First approved in 2025.
Drug data last refreshed 27m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INLEXZO is a gemcitabine intravesical system approved by the FDA in September 2025 for direct bladder instillation therapy. It functions as a nucleoside metabolic inhibitor that disrupts nucleic acid synthesis in target cells. The intravesical route delivers the drug directly to bladder tissue, minimizing systemic exposure.
Growth12.3 years to LOE
Recent launch with zero competitive pressure creates early-stage growth opportunity for commercial teams to establish market presence and build brand awareness.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Started Dec 2003
90 enrolled
Superficial Bladder Cancer
Career Relevance
INLEXZO offers early-career entry and growth opportunities in a newly launched, low-competition specialty oncology product with stable long-term patent protection. Working on this product means building market presence in a niche intravesical therapy space and capitalizing on first-mover advantage within Johnson & Johnson's oncology portfolio.
Brand Manager
Worked on INLEXZO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.